The earnings call highlighted significant clinical and regulatory progress with TSHA-102, including Breakthrough Therapy designation and strong clinical data, as well as strategic regaining of rights. However, this progress is tempered by increased expenses and net loss. Overall, the sentiment of the call leans positive due to the promising clinical results and regulatory advancements.

Company Guidance

During the third quarter of 2025 earnings call, Taysha Gene Therapies provided detailed guidance on the progress of their TSHA-102 program for Rett syndrome. The company highlighted the FDA's Breakthrough Therapy designation for TSHA-102, based on promising safety and efficacy data from the REVEAL Phase I/II trials, which showed a 100% response rate in the developmental milestones of treated patients. Taysha has aligned with the FDA on the pivotal trial protocol and statistical analysis plan, aiming for a BLA submission. The pivotal trial will enroll 15 patients with a primary endpoint of achieving a 33% response rate, equating to five out of 15 patients gaining or regaining at least one developmental milestone. Financially, Taysha reported a net loss of $32.7 million for the quarter, with research and development expenses rising to $25.7 million due to increased clinical and manufacturing activities. As of September 30, 2025, the company had $297.3 million in cash and expects this to support operations through 2028, positioning them well to advance TSHA-102 towards late-stage development and potential commercialization.

Breakthrough Therapy Designation for TSHA-102

TSHA-102 received Breakthrough Therapy designation from the FDA, highlighting its potential to redefine the treatment paradigm for Rett syndrome. Over 80% of programs with this designation that proceeded to file have received FDA approval.

Strong Clinical Data for TSHA-102

100% response rate in Part A of the REVEAL trials with 10 patients achieving developmental milestones. The data demonstrated a consistent pattern of milestone gains over time, with an 83% response rate at 6 months and 100% at 9 months post-treatment.

Regained Global Rights to TSHA-102

Taysha regained full global rights to TSHA-102 after the expiration of the option agreement with Astellas, allowing for full strategic flexibility.

Strong Financial Position

As of September 30, 2025, Taysha had $297.3 million in cash, expected to support planned expenses into 2028.

Taysha Gene Therapies (TSHA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSHA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 04, 2026	2025 (Q4)	-0.10 / -	-0.07	―	―	―
Nov 04, 2025	2025 (Q3)	-0.09 / -0.09	-0.1	10.00% (+0.01)	―
Aug 12, 2025	2025 (Q2)	-0.08 / -0.09	-0.09	0.00% (0.00)	―
May 15, 2025	2025 (Q1)	-0.09 / -0.08	-0.1	20.00% (+0.02)	―
Feb 26, 2025	2024 (Q4)	-0.08 / -0.07	0.255	-127.45% (-0.33)	―
Nov 13, 2024	2024 (Q3)	-0.09 / -0.10	-0.93	89.25% (+0.83)	―
Aug 12, 2024	2024 (Q2)	-0.16 / -0.09	-0.38	76.32% (+0.29)	―
May 14, 2024	2024 (Q1)	-0.11 / -0.10	-0.28	64.29% (+0.18)	―
Mar 19, 2024	2023 (Q4)	-0.11 / 0.26	-0.99	125.76% (+1.25)	―
Nov 14, 2023	2023 (Q3)	-0.17 / -0.93	-0.64	-45.31% (-0.29)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSHA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 04, 2025	$4.46	$4.27	-4.26%
Aug 12, 2025	$2.76	$2.91	+5.43%
May 15, 2025	$2.37	$2.56	+8.02%
Feb 26, 2025	$1.70	$1.62	-4.71%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Taysha Gene Therapies (TSHA) report earnings?

Taysha Gene Therapies (TSHA) is schdueled to report earning on Mar 04, 2026, After Close (Confirmed).

What is Taysha Gene Therapies (TSHA) earnings time?

Taysha Gene Therapies (TSHA) earnings time is at Mar 04, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSHA EPS forecast?

TSHA EPS forecast for the fiscal quarter 2025 (Q4) is -0.1.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing